220 related articles for article (PubMed ID: 38279998)
1. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
[TBL] [Abstract][Full Text] [Related]
2. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
4. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder.
Wang X; Liu M; Zhang J; Brown NK; Zhang P; Zhang Y; Liu H; Du X; Wu W; Devenport M; Tao W; Mao-Draayer Y; Chen GY; Chen YE; Zheng P; Liu Y
Cell Metab; 2022 Aug; 34(8):1088-1103.e6. PubMed ID: 35921817
[TBL] [Abstract][Full Text] [Related]
5. The biological roles of CD24 in ovarian cancer: old story, but new tales.
Gu Y; Zhou G; Tang X; Shen F; Ding J; Hua K
Front Immunol; 2023; 14():1183285. PubMed ID: 37359556
[TBL] [Abstract][Full Text] [Related]
6. CD24-Siglec interactions in inflammatory diseases.
Liu Y; Zheng P
Front Immunol; 2023; 14():1174789. PubMed ID: 37228622
[TBL] [Abstract][Full Text] [Related]
7. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
Chen C; Zhang L; Ruan Z
Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
[TBL] [Abstract][Full Text] [Related]
8. Novel insights into the function of CD24: A driving force in cancer.
Altevogt P; Sammar M; Hüser L; Kristiansen G
Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
[TBL] [Abstract][Full Text] [Related]
9. Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway.
Wang K; Yu A; Liu K; Feng C; Hou Y; Chen J; Ma S; Huang L; Dai X
Adv Sci (Weinh); 2023 May; 10(13):e2300288. PubMed ID: 36866919
[TBL] [Abstract][Full Text] [Related]
10. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.
Toubai T; Hou G; Mathewson N; Liu C; Wang Y; Oravecz-Wilson K; Cummings E; Rossi C; Evers R; Sun Y; Wu J; Choi SW; Fang D; Zheng P; Liu Y; Reddy P
Blood; 2014 May; 123(22):3512-23. PubMed ID: 24695850
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD24 as a novel immunotherapy for solid cancers.
Yang Y; Zhu G; Yang L; Yang Y
Cell Commun Signal; 2023 Nov; 21(1):312. PubMed ID: 37919766
[TBL] [Abstract][Full Text] [Related]
12. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.
Chen GY; Tang J; Zheng P; Liu Y
Science; 2009 Mar; 323(5922):1722-5. PubMed ID: 19264983
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism of Tumor Cell Immune Escape Mediated by CD24/Siglec-10.
Yin SS; Gao FH
Front Immunol; 2020; 11():1324. PubMed ID: 32765491
[TBL] [Abstract][Full Text] [Related]
14. Leishmania donovani Utilize Sialic Acids for Binding and Phagocytosis in the Macrophages through Selective Utilization of Siglecs and Impair the Innate Immune Arm.
Roy S; Mandal C
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004904. PubMed ID: 27494323
[TBL] [Abstract][Full Text] [Related]
15. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
16. Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.
Chen GY; Brown NK; Zheng P; Liu Y
Glycobiology; 2014 Sep; 24(9):800-6. PubMed ID: 24996822
[TBL] [Abstract][Full Text] [Related]
17. CD24: A Novel Target for Cancer Immunotherapy.
Panagiotou E; Syrigos NK; Charpidou A; Kotteas E; Vathiotis IA
J Pers Med; 2022 Jul; 12(8):. PubMed ID: 36013184
[TBL] [Abstract][Full Text] [Related]
18. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns.
Liu Y; Chen GY; Zheng P
Trends Immunol; 2009 Dec; 30(12):557-61. PubMed ID: 19786366
[TBL] [Abstract][Full Text] [Related]
19. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Yu Y; Peng W
Cancer Biol Med; 2023 May; 20(5):369-84. PubMed ID: 37133224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
